On December 19, 2025, Symbiotec Pharmalab Ltd. filed its Draft Red Herring Prospectus (DRHP) with SEBI to raise funds through an Initial Public Offer (IPO). The proposed issue will include a fresh issue of ₹150 crore and an offer for sale (OFS) of ₹2,030 crore, taking the total size to ₹2,180 crore.
The equity shares are proposed to be listed on NSE and BSE. Key details such as IPO dates, price band, and lot size are yet to be announced.
The IPO will be a Book Build Issue comprising two components: a fresh issue and an OFS. The fresh issue is valued at ₹150 crore, while the OFS will involve ₹2,030 crore worth of shares.
JM Financial Ltd. will act as the book running lead manager for the issue. MUFG Intime India Pvt. Ltd. has been appointed as the registrar.
Incorporated in 2002, Symbiotec Pharmalab Ltd. is engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves both domestic and international markets across regulated and emerging regions.
It focuses on research-driven manufacturing, quality compliance, and sustainable processes. Its offerings support pharmaceutical, nutraceutical, and wellness industries with high-quality, innovative ingredients.
Symbiotec Pharmalab brings over 30 years of industry experience, having evolved from a lab-scale steroidal-hormone API manufacturer in 1995 to an industrial-scale, backward-integrated platform. The company has built capabilities across the value chain over the years.
It holds approvals from leading global regulators, including the US FDA, EU-GMP and Korea’s Ministry of Food and Drug Safety. These certifications allow it to serve regulated markets across multiple geographies.
As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities. These units together had a maximum chemical synthesis capacity of 584.67 metric tonnes.
They also operate a fermentation capacity of 300 kilolitres. This infrastructure supports large-scale production while meeting international regulatory standards.
Read More: Private Equity Firm Gaja Capital Files Updated DRHP with SEBI for IPO, Plans to Raise ₹656 Crore.
Symbiotec Pharmalab’s proposed IPO seeks to raise ₹2,180 crore through a mix of fresh issue and offer for sale. The company benefits from strong regulatory approvals across key global markets.
Its integrated manufacturing capabilities and international reach position it as a notable player in the pharmaceutical and biotechnology sector. The planned listing on the NSE and BSE is expected to support expansion and enhance market visibility.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Dec 23, 2025, 1:56 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
